Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Hereditary Angioedema (HAE) Pipeline Drugs Development Market Overview

Hereditary Angioedema (HAE) is a rare inherited disease that causes considerable swelling in various body tissues, such as the abdomen or face. Symptoms include severe abdominal pain and cramping, dehydration, diarrhea and shock, hoarse voice, difficulty swallowing and difficulty breathing. Treatment includes medications, such as epinephrine, antihistamines, and corticosteroids.

The Hereditary Angioedema pipeline drugs market research report provides comprehensive information on the therapeutics under development for Hereditary Angioedema, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report offers an overview of key players involved in therapeutic development for Hereditary Angioedema and features dormant and discontinued projects.

Hereditary Angioedema Pipeline Drugs Market Segmentation by Targets

Some of the targets of the Hereditary Angioedema pipeline drugs market are Plasma Kallikrein, Coagulation Factor XII, Complement C1s Subcomponent, Plasma Protease C1 Inhibitor, and B2 Bradykinin Receptor. Plasma Kallikrein led this segment of the Hereditary Angioedema pipeline drugs market in 2022.

Hereditary Angioedema Pipeline Drugs Market Analysis by Targets, 2022 (%)

For more Hereditary Angioedema pipeline drugs market target insights, download a free report sample

Hereditary Angioedema Pipeline Drugs Market Segmentation by Mechanisms of Action

Some of the key mechanisms of action of the Hereditary Angioedema pipeline drugs market are Plasma Kallikrein Inhibitor, Coagulation Factor XII Inhibitor, Complement C1s Subcomponent Inhibitor, Plasma Protease C1 Inhibitor Activator, B2 Bradykinin Receptor Antagonist, and Plasma Protease C1 Inhibitor Replacement. Plasma Kallikrein Inhibitor accounted for the largest Hereditary Angioedema pipeline drugs market share in terms of MoA in 2022.

Hereditary Angioedema Pipeline Drugs Market Analysis by Mechanisms of Action, 2022 (%)

For more mechanisms of action insights into the Hereditary Angioedema pipeline drugs market, download a free report sample

Hereditary Angioedema Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the Hereditary Angioedema pipeline drugs market are subcutaneous, intravenous, oral, intradermal, and intramuscular. In 2022, the subcutaneous segment led the Hereditary Angioedema pipeline drugs market in terms of RoA.

Hereditary Angioedema Pipeline Drugs Market Analysis by Routes of Administration, 2022 (%)

For more routes of administration insights into the Hereditary Angioedema pipeline drugs market, download a free report sample

Hereditary Angioedema Pipeline Drugs Market Segmentation by Molecule Types

The molecule types in the Hereditary Angioedema pipeline drugs market are small molecule, monoclonal antibody, recombinant protein, gene therapy, antisense oligonucleotide, oligonucleotide, protein, and gene-modified cell therapy. Small molecule held the largest Hereditary Angioedema pipeline drugs market share in terms of molecule types.

Hereditary Angioedema Pipeline Drugs Market Analysis by Molecule Types, 2022 (%)

For more molecule-type insights into the Hereditary Angioedema pipeline drugs market, download a free report sample

Hereditary Angioedema Pipeline Drugs Market - Competitive Landscape

Some of the key companies in the Hereditary Angioedema pipeline drugs market are CSL Ltd, Kalvista Pharmaceuticals Inc, Pharming Group NV, and Attune Pharmaceuticals among others. CSL Ltd Inc had the highest number of products under development in 2022.

CSL Ltd: CSL Ltd (CSL) discovers, develops, manufactures, commercializes, and distributes biopharmaceuticals and related products. Its portfolio encompasses plasma-derived products for the treatment of hemophilia, hereditary angioedema, von Willebrand disease, inherited primary and secondary immune deficiencies, respiratory disease, neurological disorders, and protein-based medicines for treating serious human illnesses. The company also provides products for the prevention of hemolytic disease in newborns, infection in solid organ transplant recipients and to treat specific infections for victims of trauma and burns. CSL markets an array of vaccines, anti-venom, and pharmaceutical products for various other manufacturers. The company sells its products in Australia, Germany, Switzerland, the UK, the US and other countries. CSL is headquartered in Parkville, Victoria, Australia.

Hereditary Angioedema Pipeline Drugs Market Analysis by Companies, 2022 (%)

To know more about the Hereditary Angioedema pipeline drugs market companies, download a free report sample

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Hereditary Angioedema.
• The pipeline guide reviews pipeline therapeutics for Hereditary Angioedema by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Hereditary Angioedema therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Hereditary Angioedema therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews the latest news related to pipeline therapeutics for Hereditary Angioedema

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with a potentially strong product portfolio and create effective counterstrategies to gain a competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Hereditary Angioedema.
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding the Hereditary Angioedema pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.